Brian J Sisko Net Worth

The estimated Net Worth of Brian J Sisko is at least $59.9 Thousand dollars as of 10 December 2018. Brian Sisko owns over 2,500 units of Safeguard Scientifics stock worth over $59,886 and over the last 17 years Brian sold SFE stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Brian Sisko SFE stock SEC Form 4 insiders trading

Brian has made over 10 trades of the Safeguard Scientifics stock since 2011, according to the Form 4 filled with the SEC. Most recently Brian bought 2,500 units of SFE stock worth $22,975 on 10 December 2018.

The largest trade Brian's ever made was exercising 25,000 units of Safeguard Scientifics stock on 17 August 2015 worth over $316,000. On average, Brian trades about 1,172 units every 29 days since 2007. As of 10 December 2018 Brian still owns at least 130,186 units of Safeguard Scientifics stock.

You can see the complete history of Brian Sisko stock trades at the bottom of the page.

What's Brian Sisko's mailing address?

Brian's mailing address filed with the SEC is 1 RADNOR CORPORATE CTR., SUITE 110, 100 MATSONFORD ROAD, RADNOR, PA, 19087.

Insiders trading at Safeguard Scientifics

Over the last 21 years, insiders at Safeguard Scientifics have traded over $372,519 worth of Safeguard Scientifics stock and bought 877,847 units worth $3,711,567 . The most active insiders traders include Stephen Fisher, Thomas A Jr Satterfield, and Michael F Cola. On average, Safeguard Scientifics executives and independent directors trade stock every 51 days with the average trade being worth of $7,022. The most recent stock trade was executed by Thomas A Jr Satterfield on 17 August 2023, trading 294,000 units of SFE stock currently worth $346,920.

What does Safeguard Scientifics do?

safeguard scientifics (nyse:sfe) provides capital and relevant expertise to fuel the growth of technology-driven businesses in healthcare, financial services and digital media. safeguard targets companies that are capitalizing on the next wave of enabling technologies with a particular focus on the internet of everything, enhanced security and artificial intelligence, which includes predictive analytics and machine learning. safeguard typically deploys between $5 million and $25 million over the course of its partnership with a company, initially investing in a series a or b round and opportunistically in a seed round. safeguard has a distinguished track record of fostering innovation and building market leaders that spans more than six decades.

Complete history of Brian Sisko stock trades at Safeguard Scientifics

Safeguard Scientifics executives and stock owners

Safeguard Scientifics executives and other stock owners filed with the SEC include:

• Eric C. Salzman,
  Chief Exec. Officer
• Mark A. Herndon CPA,
  Sr. VP & CFO
• Mark Herndon,
  Chief Financial Officer, Senior Vice President
• Robert Rosenthal,
  Executive Chairman of the Board, Principal Executive Officer
• Maureen Morrison,
  Independent Director
• Russell Glass,
  Independent Director
• Joseph Manko,
  Independent Director
• Eric Salzman,
  Chief Restructuring Officer
• Seth Zuckerman,
  Sr. Associate of Healthcare
• Alex A. Fuiks,
  Associate
• Steven J. Grenfell CPA, CPA,
  Sr. Advisor
• Dr. Gary J. Kurtzman M.D.,
  Sr. Advisor
• G. Matthew Barnard,
  Gen. Counsel, Sec. & Compliance Officer
• David A Kille,
  Senior VP & CFO
• Brian J Sisko,
  President & CEO
• Bob Rosenthal,
  Director
• Jeffrey Brian Mc Groarty,
  Senior VP - Finance
• Stephen T Zarrilli,
  Acting Sr VP & Acting CFO
• Julie A Dobson,
  Director
• John Joseph Roberts,
  Director
• George Mackenzie,
  Director
• Stephen Fisher,
  Director
• Beth Michelson,
  Director
• Ross D De Mont,
  Director
• Ira M Lubert,
  Director
• Thomas A Jr Satterfield,
  10% owner
• Keith B Jarrett,
  Director
• Peter J Boni,
  President & CEO
• Jack L Messman,
  Director
• George D Mcclelland,
  Director
• James A Datin,
  Executive Vice President
• Mara G. Aspinall,
  Director
• Kevin L Kemmerer,
  Sr. VP & Managing Director
• Michael J Cody,
  Director
• Robert Ripp,
  Director
• Anthony L Craig,
  President & CEO
• Christopher J Davis,
  Managing Director and CFO
• John William Sr Poduska,
  Director
• Steven J Feder,
  Sr. V.P. & General Counsel
• Robert E Jr Keith,
  Director
• Michael F Cola,
  Managing Director
• Raymond J Land,
  Senior V.P. & CFO
• John A Loftus,
  Sr. Vice President & CTO
• Anthony Ibarguen,
  Managing Director
• Russell E Palmer,
  Director